| |
WT
|
CORT-KO
|
SST-KO
|
|---|
| |
LF (n = 39)
|
HF (n = 43)
|
LF (n = 33)
|
HF (n = 24)
|
LF (n = 23)
|
HF (n = 30)
|
|---|
|
Whole-mount analysis
|
|
Tumor
|
3 %
|
5 %
|
14 %##
|
13 %
|
4 %$
|
3 %$
|
|
Hyperplasia
|
16 %
|
35 %**
|
10 %
|
25 %**
|
13 %
|
38 %***
|
|
Normal
|
81 %
|
60 %**
|
76 %
|
63 %
|
83 %
|
59 %**
|
|
Percentage of mice that were not included in the studya
|
35 %
|
24.5 %
|
21.4 %
|
40 %
|
30.3 %
|
23 %
|
- **p <0.01, ***p <0.001, for mice fed a low fat (LF) diet vs high fat (HF) diet (within the same genotype); ##
p <0.01 in wild-type (WT) vs knockout (KO) mice (within the same diet group); $
p <0.05) in cortistatin (CORT)-KO vs somatostatin (SST)-KO (within the same diet group). aMice that died during the 3 weeks of 7, 12 dimethylbenz[α]anthracene (DMBA) administration or during the weeks immediately subsequent, due to the toxicity of this compound and/or the invasiveness of the method used to deliver DMBA, were not included in the study
